0000919574-20-005488.txt : 20200821
0000919574-20-005488.hdr.sgml : 20200821
20200821175647
ACCESSION NUMBER: 0000919574-20-005488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200819
FILED AS OF DATE: 20200821
DATE AS OF CHANGE: 20200821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ARMISTICE CAPITAL, LLC
CENTRAL INDEX KEY: 0001601086
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 201124312
BUSINESS ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 231-4932
MAIL ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Armistice Capital Master Fund Ltd.
CENTRAL INDEX KEY: 0001633584
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 201124313
BUSINESS ADDRESS:
STREET 1: C/O ARMISTICE CAPITAL, LLC
STREET 2: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-231-4932
MAIL ADDRESS:
STREET 1: C/O ARMISTICE CAPITAL, LLC
STREET 2: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyd Steven
CENTRAL INDEX KEY: 0001706140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 201124314
MAIL ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0000034956
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 262593535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE COPLEY PARKWAY
STREET 2: SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-806-4414
MAIL ADDRESS:
STREET 1: ONE COPLEY PARKWAY
STREET 2: SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC.
DATE OF NAME CHANGE: 20080703
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SINEQUANON CORP
DATE OF NAME CHANGE: 19901219
4
1
ownership.xml
X0306
4
2020-08-19
0
0000034956
TENAX THERAPEUTICS, INC.
TENX
0001601086
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK
NY
10022
1
0
1
0
0001633584
Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD.
20 GENESIS CLOSE, P.O. BOX 314
GRAND CAYMAN
E9
KY1-1104
CAYMAN ISLANDS
1
0
1
0
0001706140
Boyd Steven
C/O ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK
NY
10022
1
0
1
0
Common Stock
2020-08-19
4
P
0
70767
1.45
A
1594378
D
Common Stock
2020-08-19
4
P
0
0
0
A
1594378
I
See Footnote
Common Stock
2020-08-20
4
P
0
124472
1.53
A
1718850
D
Common Stock
2020-08-20
4
P
0
0
0
A
1718850
I
See Footnote
Common Stock
2020-08-21
4
P
0
116242
1.44
A
1835092
D
Common Stock
2020-08-21
4
P
0
0
0
A
1835092
I
See Footnote
The reported securities (the "Shares") are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This constitutes the weighted average purchase price. The prices ranged from $1.38 to $1.46. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices ranged from $1.45 to $1.60. The Reporting Person will provide upon request by the SEC Staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices ranged from $1.42 to $1.51. The Reporting Person will provide upon request by the SEC Staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member
2020-08-21
Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Managing Member
2020-08-21
/s/ Steven Boyd
2020-08-21